Interferon biology and LAG3 shedding in PD-(L)1 plus LAG3 immunotherapy.
Lilit KarapetyanJason John LukePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Targeting coinhibitory receptors on dysfunctional T cells may improve response to anti-PD-(L)1 in the interferon-γ associated T cell-inflamed tumor microenvironment. The bispecific LAG-3 and PD-L1 blocking antibody FS118, potentially through LAG-3 shedding, represents a promising strategy to improve immune-checkpoint blockade. Soluble LAG-3 is an intriguing biomarker for LAG-3 drug activity.